BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotech...

June 16, 2022 | News

Evonik launches new peptide to boost productivity of cell-culture-based biopharmaceuticals

Evonik now offers a highly pure cystine peptide to address challenges in the formulation of cell culture media and processes used in the development and pr...

June 07, 2022 | News

CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer

CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative im...

June 07, 2022 | News

4P-Pharma and Delta 4 Join Forces to Find and Develop Treatments for a Rare Autoimmune Chronic Liver Disease

Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeuti...

June 03, 2022 | News

United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria

This Phase 2 clinical trial (double-blind, placebo-controlled) aims to evaluate the efficacy of UB-221 as a long-acting add-on therapy for treatment of chr...

May 31, 2022 | News

I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression corr...

May 27, 2022 | News

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

The 2022 CSCO Guidelines incorporate a total of four selinexor combination therapy regimens for relapsed myeloma. In addition, the guidelines also recommen...

May 13, 2022 | News

Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV

As disclosed in the prospectus of the Company dated March 21, 2022, the Group had initiated subject enrollment for the phase II/III clinical trial for...

May 06, 2022 | News

Inmagene Receives FDA's IND Clearance for OX40 Antagonist

IMG-007 is highly potent at blocking the binding of OX40 to OX40L, thereby reducing OX40L-dependent downstream signaling and cytokine release by T cells. I...

May 02, 2022 | News

Lessons Learned from COVID-19 Vaccine Trials

IQVIA Institute releases report on Lessons Learned from COVID-19 Vaccine Trials Solutions for you to dri...

April 28, 2022 | News

FDA Approves Direct Biologics to Proceed with a Landmark Phase 3 Acute Respiratory Distress Syndrome (ARDS) Trial

The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the FDA for an EV...

April 28, 2022 | News

PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study

PMC-403 can stabilize and repair damaged and pathologically leaky blood vessels, and it is being developed to treat AMD (Age-related Macular Degeneration),...

April 27, 2022 | News

Lynk Pharmaceuticals Announces Clinical Approval in China for Its Class I New Drug LNK01004

LNK01004 is a novel kinase inhibitor that can simultaneously inhibit multiple inflammatory cytokines and block multiple signaling pathways related to psori...

April 25, 2022 | News

TauRx's late-stage clinical trial reaches new milestone

TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed treatment in t...

April 14, 2022 | News

Stay Connected